Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity

被引:62
作者
Mori, Yutaka
Itoh, Yohta
Tajima, Naoko
机构
[1] Utsunomiya Natl Hosp, Natl Hosp Org, Dept Internal Med, Kawachi, Tochigi 3291193, Japan
[2] Jikei Univ, Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Tokyo, Japan
关键词
telmisartan; adipocyte; insulin resistance; hypertriglyceridemia;
D O I
10.1016/j.amjhyper.2006.09.016
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective: To investigate the influence of blockade of the renin-angiotensin system (RAS) on adipocytes, we compared the effect of telmisartan versus valsartan and amlodipine on adipocyte cellularity in the spontaneously type 2 diabetic, obese rat model. Methods: Male Otsuka Long Evans Tokushima Fatty rats, 8-week-old, were divided into four groups as follows: valsartan (V) group (10 mg/kg, n = 12), telmisartan (T) group (5 mg/kg, n = 12), amlodipine (A) group (2 mg/kg, n = 12), and control (C) group (n = 12). Each drug was mixed with chow and given for 16 weeks. Results: Although no significant differences were observed in the fasting plasma glucose level between the groups, the fasting plasma insulin level for group T was significantly lower than that for group C. Histopathologic examination showed that the ratio of small adipocytes in groups V and T was significantly higher than that in group C, with the ratio of large adipocytes and the mean adipocyte size shown to be significantly lower in groups V and T than in group C. Furthermore, group T was shown to have a significantly higher ratio of small adipocytes, a significantly lower ratio of large adipocytes, as well as a significantly lower mean adipocyte size, compared to group V. Conclusions: Although both valsartan and telmisartan downsized adipocytes, adipocyte downsizing was significantly greater with telmisartan compared to valsartan. The likely mechanism for this difference was thought to be the PPAR-gamma-mediated action of telmisartan.
引用
收藏
页码:431 / 436
页数:6
相关论文
共 27 条
[1]   Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice [J].
Araki, Kana ;
Masaki, Takayuki ;
Katsuragi, Isao ;
Tanaka, Katsuhiro ;
Kakuma, Tetsuya ;
Yoshimatsu, Hironobu .
HYPERTENSION, 2006, 48 (01) :51-57
[2]   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity [J].
Benson, SC ;
Pershadsingh, HA ;
Ho, CI ;
Chittiboyina, A ;
Desai, P ;
Pravenec, M ;
Qi, NN ;
Wang, JM ;
Avery, MA ;
Kurtz, TW .
HYPERTENSION, 2004, 43 (05) :993-1002
[3]   Renal function in the AT1A receptor knockout mouse during normal and volume-expanded conditions [J].
Cervenka, L ;
Mitchell, KD ;
Oliverio, MI ;
Coffman, TM ;
Navar, LG .
KIDNEY INTERNATIONAL, 1999, 56 (05) :1855-1862
[4]  
FOLCH J, 1957, J BIOL CHEM, V226, P497
[5]  
Furuhashi M, 2004, J HYPERTENS, V22, P1977, DOI 10.1097/00004872-200410000-00021
[6]   Differential expression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia [J].
Hikita, M ;
Bujo, H ;
Yamazaki, K ;
Taira, K ;
Takahashi, K ;
Kobayashi, J ;
Saito, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 277 (02) :423-429
[7]   WHICH IS THE PRIMARY ETIOLOGIC EVENT IN OTSUKA LONG-EVANS TOKUSHIMA FATTY RATS, A MODEL OF SPONTANEOUS NON-INSULIN-DEPENDENT DIABETES-MELLITUS, INSULIN-RESISTANCE, OR IMPAIRED INSULIN-SECRETION [J].
ISHIDA, K ;
MIZUNO, A ;
MIN, Z ;
SANO, T ;
SHIMA, K .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (07) :940-945
[8]   Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors [J].
Iwaki, M ;
Matsuda, M ;
Maeda, N ;
Funahashi, T ;
Matsuzawa, Y ;
Makishima, M ;
Shimomura, I .
DIABETES, 2003, 52 (07) :1655-1663
[9]   Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors [J].
Janke, J ;
Engeli, S ;
Gorzelniak, K ;
Luft, FC ;
Sharma, AM .
DIABETES, 2002, 51 (06) :1699-1707
[10]   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].
Julius, S ;
Kjeldsen, SE ;
Weber, M ;
Brunner, HR ;
Ekman, S ;
Hansson, L ;
Hua, TS ;
Laragh, J ;
McInnes, GT ;
Mitchell, L ;
Plat, F ;
Schork, A ;
Smith, B ;
Zanchetti, A .
LANCET, 2004, 363 (9426) :2022-2031